


Long-Term Safety and Efficacy of Oral Deucricitbant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results

John Anderson¹, Emel Ayygören-Pürsün², Henriette Farkas³, Joshua S. Jacobs⁵, Michael E. Manning⁶, Anna Valerieva⁷, Giorgio Giannattasio⁸, Yumeng Li⁹, Ming Yu⁹, Marc A. Riedl¹⁰

¹AllerVie Health, Clinical Research Center of Alabama, Birmingham, AL, USA; ²Goethe University Frankfurt, Department of Pediatrics, Frankfurt am Main, Germany; ³Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary; ⁴St. Anne's University Hospital in Brno and Faculty of Medicine, Masaryk University, Czech Republic; ⁵Allergy and Asthma Clinical Research, Walnut Creek, CA, USA; ⁶Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, AZ, USA; ⁷Medical University of Sofia, Department of Allergology, Sofia, Bulgaria; ⁸Pharvaris GmbH, Zug, Switzerland; ⁹Pharvaris Inc., Lexington, MA, USA; ¹⁰University of California San Diego, Division of Allergy and Immunology, La Jolla, CA, USA

Key takeaways

Final Part A results from the RAPIDe-2 extension study are consistent with the Phase 2 RAPIDe-1 study and provide further evidence on the long-term safety and efficacy of deucricitbant immediate-release (IR) capsule for treatment of repeat hereditary angioedema (HAE) attacks.



Background

- Hereditary angioedema (HAE):** a bradykinin-mediated condition with painful swelling attacks affecting multiple locations in the body.¹
- Unmet need:** guidelines recommend HAE attacks are treated as early as possible.²⁻⁴ Parenteral administration often leads to on-demand treatment of HAE attacks being delayed, or forgone.⁵⁻⁸
- Deucricitbant:** a selective, investigational, orally administered, bradykinin B2 receptor antagonist under development for both prophylactic and on-demand treatment of HAE attacks.⁹⁻¹⁶


Objective

To evaluate the long-term safety and efficacy of deucricitbant immediate-release (IR) capsule for on-demand treatment of repeat HAE attacks in the RAPIDe-2 extension study.

Methods

- RAPIDe-2 (NCT05396105)*:** a two-part, Phase 2/3 long-term extension study.¹¹
- Part A eligible participants:** adults who completed RAPIDe-1 (NCT04618211).⁹
- Part A prophylaxis:** no long-term HAE prophylaxis treatment was allowed. Recent use of long-term HAE prophylaxis treatment prior to screening was allowed provided a pre-specified washout period was observed.

Figure 1. RAPIDe-2 study design



Methods

- Primary endpoint:** safety, including treatment-emergent adverse events (TEAEs), clinical laboratory tests, vital signs, and electrocardiogram (ECG) findings.
- Secondary endpoints:** efficacy endpoints using patient-reported outcome tools.
- Data collection:** pre-specified at pre-treatment, hourly for 6 hours, and at 8, 12, 24, and 48 hours post-treatment.

Figure 2. Efficacy assessment scales



Table 1. Efficacy endpoints

Key efficacy endpoints	Defined as
Time to and proportion of attacks achieving:	
Onset of symptom relief	PGI-C rating of at least "a little better" for 2 consecutive timepoints by 12 hours ^a
Substantial symptom relief	PGI-C rating of at least "better" for 2 consecutive timepoints by 12 hours ^a
Reduction in attack severity	≥1-level reduction in the PGI-S from pre-treatment for 2 consecutive timepoints by 12 hours ^a
Complete attack resolution	PGI-S rating of "none" at 24 hours ^b

PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. ^aIf rescue medication used within 14.5 hours post-treatment, time to event was censored at 14.5 hours regardless of whether event occurred within 12 hours post-treatment. ^bRescue medication use within 33.5 hours post-treatment was regarded as not achieving complete attack resolution at 24 hours.

Post hoc analyses

- Durability of treatment response:** the achievement and maintenance of serial milestones of symptom relief and resolution without recurrence of symptoms following a single dose of deucricitbant only.
- Symptom recurrence:** following the achievement of each efficacy milestone, symptom recurrence was evaluated as any instance where the milestone was no longer being met within 24 hours.

Results

Data:

- RAPIDe-2 Part A included 465 attacks from 19 participants. Combined dose-blinded group data are shown.

Table 2. Participant characteristics

Participant characteristics	Deucricitbant IR capsule (combined dose group) ^a (N=19)
Age in years, mean (SD)	44.4 (17.6)
Sex: male / female, n (%)	7 (36.8) / 12 (63.2)
Race: White / other, n	18 / 1
BMI, mean (SD)	26.8 (4.0)
Years since HAE diagnosis, mean (SD)	23.3 (15.2)
HAE type, n (%)	
HAE-1	17 (89.5)
HAE-2	2 (10.5)

BMI, body mass index; HAE, hereditary angioedema; IR, immediate-release; SD, standard deviation. ^aAll participants who received any dose of deucricitbant in the study. Study baseline refers to results at the screening or enrollment visit of RAPIDe-2 Part A. For parameters whose values remain constant over time, baseline values from RAPIDe-1 were used. For parameters without results at the screening or enrollment visit of RAPIDe-2 or for parameters not collected at that time, the last available assessment in RAPIDe-1 was used as the baseline values. Data for combined dose group shown (deucricitbant 10 mg, 20 mg, and 30 mg).

Results

Safety analysis (Part A)

- Participants who received at least one dose of deucricitbant IR capsule in the study.
- No treatment-related TEAEs.
- No treatment-related serious or severe TEAEs, no treatment-related TEAEs in laboratory parameters, vital signs, or ECG findings.
- No TEAEs leading to treatment discontinuation, study withdrawal, or death.

Table 3. TEAEs within 3 days of study drug administration

Adverse events	Deucricitbant IR capsule (combined dose group) (N=19; A=465)
Attacks with any TEAE, n (%)	12 (2.6)
Treatment-related TEAEs, n	0
Serious TEAEs, n	1 ^a
Treatment-related serious TEAEs, n	0
TEAEs leading to study drug discontinuation, study withdrawal, or death, n	0

IR, immediate-release; TEAE, treatment-emergent adverse event, defined as adverse event occurring from first study drug administration. A = number of treated attacks. N = number of participants. ^aTooth caries unrelated to treatment. Data for combined dose group shown (deucricitbant 10 mg, 20 mg, and 30 mg).

Efficacy analysis (Part A)


- Modified intention-to-treat analysis set: participants who treated at least one attack with deucricitbant IR capsule and non-missing Patient Global Impression of Change (PGI-C) results from at least one post-treatment timepoint.

Figure 3. Median time to achieving key efficacy endpoints




CI, confidence interval; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. ^aPGI-C rating of at least "a little better" for 2 consecutive timepoints by 12 hours post-treatment regardless of any missing intervening assessments and without rescue medication use. ^bWithin-participant correlation was not accounted for in all Kaplan-Meier estimates. ^cPGI-C rating of at least "better" for 2 consecutive timepoints by 12 hours post-treatment regardless of any missing intervening assessments and without rescue medication use. ^d≥1-level reduction in PGI-S from pre-treatment for 2 consecutive timepoints by 12 hours post-treatment and without rescue medication use. ^ePGI-S rating of "none" within 48 hours post-treatment and without rescue medication use.

Figure 4. Majority of attacks achieved key efficacy endpoints



Results


Figure 5. Majority of attacks treated with a single dose of deucricitbant IR capsule and without rescue medication



IR, immediate-release; PGI-S, Patient Global Impression of Severity. A = number of attacks. Data for combined dose group shown (deucricitbant 10 mg, 20 mg, and 30 mg). ^aProportion of attacks that were not treated with rescue medication within 24 hours post-treatment; 8 attacks used rescue medication within 24 hours post-treatment. ^bProportion of attacks achieving complete attack resolution, defined as achieving PGI-S rating of "none" at the last available timepoint before or at 24 hours post-treatment without use of rescue medication.

Durability of response to treatment

Figure 6. Over 98% of attacks that achieved symptom relief or resolution with a single dose of deucricitbant IR capsule had a durable response without symptom recurrence



IR, immediate-release; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. A = number of study-drug treated attacks that achieved the efficacy milestone with a single dose of deucricitbant. ^aDefined as PGI-C rating remaining "same" or "better" within 24 hours after reaching "a little better" for 2 consecutive timepoints within 12 hours post-treatment. ^bDefined as PGI-S rating better than "none" within 24 hours after reaching "none" within 24 hours post-treatment. Combined dose group data shown (deucricitbant 10 mg, 20 mg, and 30 mg).

This presentation includes data for an investigational product not yet approved by regulatory authorities.

References

- Busse PJ, et al. *N Engl J Med*. 2020;382:1136-48.
- Betschel S, et al. *Allergy Asthma Clin Immunol*. 2019;15:72.
- Busse PJ, et al. *J Allergy Clin Immunol Pract*. 2021;9:132-50.
- Maurer M, et al. *Allergy*. 2022;77:1961-90.
- Center for Biologics Evaluation and Research. The voice of the patient—hereditary angioedema. US Food and Drug Administration; May 2018. <https://www.fda.gov/media/113509/download>. Accessed September 22, 2025.
- Betschel SD, et al. *Allergy Asthma Clin Immunol*. 2024;20:43.
- Covella B, et al. *Future Pharmac*. 2024;4:1-53.
- Christiansen S, et al. *Ann Allergy Asthma Immunol*. 2025;134(5):570-579.
- RAPIDe-1 <https://www.clinicaltrials.gov/study/NCT04618211>. Accessed September 22, 2025.
- Maurer M, et al. Presented at: AAAAI; February 24–27, 2023; San Antonio, TX, USA.
- RAPIDe-2. <https://clinicaltrials.gov/study/NCT05396105>. Accessed September 22, 2025.
- RAPIDe-3. <https://www.clinicaltrials.gov/study/NCT06343779>. Accessed September 22, 2025.
- CHAPTER 1. <https://www.clinicaltrials.gov/study/NCT05047185>. Accessed September 22, 2025.
- CHAPTER 3. <https://clinicaltrials.gov/study/NCT06669754>. Accessed September 22, 2025.
- CHAPTER 4. <https://clinicaltrials.gov/study/NCT0679881>. Accessed September 22, 2025.
- CHAPTER 5. <https://clinicaltrials.gov/study/NCT0679881>. Accessed September 22, 2025.
- Ayygören-Pürsün E, et al. Presented at: EAACI; May 31–June 3, 2024; Valencia, Spain.
- Cohn DM, et al. *Clin Transl Allergy*. 2023;e12288.